Wörwag Pharma's decade of growth: Revenue doubles amid global expansion
Wörwag Pharma has reported steady growth and expansion despite global challenges. The company's revenue rose by 8% last year, reaching €359 million. Over the past decade, its business has doubled, driven by new products and international sales.
Founded in 1971 by Dr. Fritz Wörwag, the company began with Magnerot Classic. In 1985, it expanded its range with Milgamma and went global in 1993. Recent years have seen further growth, particularly with B12 Ankermann, which gained market share in German pharmacies.
Between 2021 and 2025, Wörwag's international news surged from 40% to over 60% of total revenue. Germany's share dropped from 60% to under 40%. Strong growth in Eastern Europe (+25%) and Asia—where new subsidiaries in India and China now account for 15% of global revenue—drove this shift.
The company also invested in production, acquiring sites in Łódź (2021) and Pöcking (2023). Both locations were expanded and modernised to meet rising demand. Market engagement was boosted through digital platforms, traditional media, and field sales teams.
In April, Wörwag will launch Lagosa Triplex, a patented blend of three natural ingredients. The product aims to support heart, liver, and lipid metabolism function.
Wörwag's revenue growth and international expansion highlight its resilience. The company has strengthened production, diversified its product line, and maintained stability amid regulatory and supply chain pressures. New launches like Lagosa Triplex will further shape its future direction.
